**Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report**

Ruijuan Wang†, Kao Li†, Jianjun Pi, Liwei Meng & Minli Zhu

Department of Respiratory Medicine, PLA Strategic Support Force Characteristic Medical Center, Beijing, China

**Keywords**
- Cancer; hemoptysis; immune checkpoint inhibitors; non-small cell lung.

**Correspondence**
Ruijuan Wang, Department of Respiratory Medicine, PLA Strategic Support Force Characteristic Medical Center, Beijing 100101, China.
Tel: +86 10 6635 6729-2305
Email: 13661035333@126.com;
Minli Zhu, Department of Respiratory Medicine, PLA Strategic Support Force Characteristic Medical Center, Beijing 100101, China.
Tel: +86 10 6635 6729-2305
Email: zmlxf2003@163.com

†These authors contributed equally to this work.

Received: 28 May 2020;
Accepted: 28 June 2020.

doi: 10.1111/1759-7714.13578

**Thoracic Cancer** 11 (2020) 2727–2730 © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

**Abstract**

**Abstract:** Immune checkpoint inhibitor (ICI)-related massive hemoptysis with cavitation has rarely been identified. Here, we report a case of advanced lung adenocarcinoma with lethal bleeding after eight cycles of pembrolizumab. A 55-year-old male was diagnosed with stage IV non-small cell lung cancer (NSCLC). Following confirmation of high programmed death-ligand 1 (PD-L1) expression of 60% cancer cells, he subsequently received pembrolizumab monotherapy. His symptoms and chest images significantly improved after four cycles of therapy. However, after eight cycles of immunotherapy, he presented with recurrence of bloody sputum and shortness of breath. Pembrolizumab was discontinued and a diagnosis of checkpoint inhibitor-associated pneumonitis (CIP) was made. When the CIP was absorbed after glucocorticoid therapy, the patient died of sudden massive hemoptysis with cavitation in the lesion.

**Key points:** Although checkpoint inhibitor associated pneumonitis was the leading cause of ICI-related death, clinicians should be alerted to the finding that more attention should be given to hemoptysis attributed to ICI therapy in advanced lung cancer.

**Introduction**

Compared with conventional platinum-based chemotherapy, immune checkpoint inhibitor (ICI) therapy can significantly improve progression-free survival (PFS) and overall survival (OS) of patients with non-small cell lung cancer (NSCLC). Pembrolizumab is an ICI which is recommended as first-line treatment for advanced NSCLC showing ≥50% expression of programmed death-ligand 1 (PD-L1), or treatment of patients with NSCLC whose tumors express PD-L1 ≥ 1%. As ICIs have been increasingly applied in lung cancer, immune-related adverse events (irAEs) have aroused greater attention. Checkpoint inhibitor associated pneumonitis (CIP) is the most common serious irAE, as well as the leading cause of ICI-related death. Here, we report a significantly rare case of massive hemoptysis with pulmonary cavitation after eight cycles of pembrolizumab monotherapy.

**Case report**

A 55-year-old male with a 20 pack-year smoking status was admitted to our hospital with symptoms of dyspnea and bloody sputum in July 2019. He also complained of dysphagia and was unable to lie flat. He was diagnosed with stage IV lung adenocarcinoma (Fig 1a) in April 2019 when epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genomic aberrations were determined not to be present, but he was found to have a high PD-L1 expression of 60% (Fig 1b). The patient had anaphylactic shock following brain enhanced magnetic resonance imaging (MRI) at the beginning of his illness and...
his previous medical history included short-term chemo-
therapy without any benefit before he presented at our
clinic. On admission, a significant physical examination
revealed decreased breath sounds on the right side of the
chest. Thoracic computed tomography (CT) scan showed a
giant mass lesion in the right lung with obvious compres-
sion of trachea, right brain bronchus and part of the
esophagus (Fig 2a). Given the high PD-L1 expression of
tumor cells, the patient received pembrolizumab mon-
otherapy (100 mg/bodyweight) once every three weeks
from 31 July. Subsequent surveillance with CT scan rev-
ealed shrinkage in the size of the mass but there was a
large low density necrotic area in the center and significant
compression release of the trachea and esophagus after
four cycles (week 12) of ICI therapy (Fig 2b). All the symp-
toms present on admission were relieved. His efficacy was
considered as a partial response (PR) which complied with
the Response Evaluation Criteria in Solid Tumors (REC-
IST). Moreover, his performance status, abiding by the
Eastern Cooperative Oncology Group (ECOG), was ele-
vated from four prior to therapy to one. After 24 weeks
of treatment with pembrolizumab, he returned to the clinic
with recurrence of hemoptysis and shortness of breath,
which coincided with the most serious period of the 2019
coronavirus disease (COVID-19) in China. He had never
been to Wuhan, nor had he had any contact with COVID-
19 patients. His temperature had been normal since the onset of disease, and breath sounds on the right side of his chest were significantly stronger than previously. There had been no administration of any anticoagulants or antiplatelet agent. Moreover, the results of his blood count, chemistry and coagulation tests were normal. CT scan showed progressive subpleural consolidation in the left lung after anti-infection treatment and a small transparent area was visible within the mass lesion in the right lung (Fig 2c). Pembrolizumab was stopped later (week 25) after a diagnosis of CIP (grade 3). Methylprednisolone treatment (40 mg b.i.d.) was initiated, which was decreased with subsequent regression of the left pulmonary lesions (Fig 2d). However, the patient’s symptoms were not completely relieved. Furthermore, he still presented with hemoptysis, along with cavitation in the lesion in the right lung. On week 28, the patient died of sudden massive hemoptysis.

Discussion

Hemoptysis is one of the most frequent symptoms of lung cancer and its pathophysiology remains unclear. Pulmonary hemorrhage or hemoptysis events related to tumor treatment are often reported in clinical trials of NSCLC as the most common adverse events of antiangiogenic drugs, such as bevacizumab.1-4 Some of these events are severe and even lead to fatal outcomes. However, different studies have achieved inconsistent risk factors of bleeding. In a randomized phase II study, 9% of bevacizumab-treated patients experienced a life-threatening bleeding event and major hemoptysis was found to be related to squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels.5 As revealed in another retrospective case control analysis suggested that tumor cavitation at baseline could be a potential risk factor in bevacizumab-treated patients developing hemoptysis, while lesion location, size or vascular involvement appeared to be slightly related to severe hemoptysis.6 As revealed by a consensus from a panel of experts,7 patients with those risk factors of squamous cell carcinoma and a history of hemoptysis were restricted in bevacizumab use. No other clinical radiological features (including cavitation and central tumor location) could reliable predict severe pulmonary hemorrhage in bevacizumab-treated patients, whereas major blood vessel infiltration and bronchial vessel infiltration, encasement and abutting may predict pulmonary hemorrhage.

Pneumonitis is the most common serious AE associated with pembrolizumab in lung cancer trials and the leading AE that causes pembrolizumab discontinuation.8 CIP is also the leading cause of ICI-related death.9 Bleeding events have been rarely reported with ICIs in clinical trials and the relevant risk factors are poorly understood. Five lethal bleeding cases have been previously reported when atezolizumab was combined with chemotherapy and bevacizumab in nonsquamous NSCLC, four of which occurred in patients with potential high-risk features, such as tumor infiltration of great vessels or cavitation.10 Another two fatal cases of hemoptysis have been previously reported after the first dose of pembrolizumab in patients with lung adenocarcinoma.11,12 As suggested by the authors, the achievement of a great response and rapid tumor shrinkage after treatment with ICIs may lead to massive hemoptysis in NSCLC with central localization, vascular involvement, as well as high PD-L1 expression.

In the present study, we report a case of lesion shrinkage after four cycles of pembrolizumab monotherapy and recurrent hemoptysis accompanied by CIP after eight cycles. The body temperature of the patient in our study was consistently normal, laboratory findings were not indicative of bacteria or fungal infection, and corticosteroids were not used before the appearance of the low density shadow and subsequent transparent area following ICI therapy. Accordingly, the cavity formation and hemoptysis could not have been associated with corticosteroid therapy, nor were they consistent with aspergillus infection. The case in our study is inconsistent with that reported by Zarogoulidis13 et al. in which a lung mass turned into an abscess together with the patient suffering from fever, infection indicated by laboratory findings and effective antibiotic treatment. Reviewing the studies of hemoptysis related to tumor treatment together with the findings in our case, we believe that the severe bleeding event was caused by the giant central location of the tumor that was significantly PD-L1 positive, shrinkage of the mass and large area necrosis with cavity formation after immunotherapy, as well as possible vascular involvement. However, in our case, vascular involvement was unclear as it was impacted by the lack of enhanced CT as a result of MRI contrast medium allergy in the patient; in addition, patient autopsy was refused. In conclusion, this study alerts clinicians to place more emphasis on hemoptysis which could be associated with the use of ICIs in NSCLC.

Acknowledgments

We thank Dr Jianzhong Zhang for his assistance in the English revision of this article.

Disclosure

No authors report any conflict of interest.
References
1 Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50.
2 Niho S, Kunitoh H, Nokihara H et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012; 76: 362–7.
3 Reck M, von PJ, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227–34.
4 Dansin E, Cinieri S, Garrido P et al. MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer 2012; 76: 373–9.
5 Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184–91.
6 Sandler AB, Schiller JH, Gray R et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009; 27: 1405–12.
7 Reck M, Barlesi F, Crinò L et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: A consensus report from a panel of experts. Ann Oncol 2012; 23: 1111–20.
8 Pai-Scherf L, Blumenthal GM, Li H et al. FDA approval summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: First-line therapy and beyond. Oncologist 2017; 22: 1392–9.
9 Wang X, Wu S, Chen Y et al. Fatal adverse events associated with programmed cell death ligand 1 inhibitors: A systematic review and meta-analysis. Front Pharmacol 2020; 11: 5.
10 Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288–301.
11 Facchinetti F, Majori M, Sabato M, Gnetti L, Tiseo M. Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: Did tumor shrinkage matter. Immunotherapy 2019; 11: 161–6.
12 Artal-Cortés A, Felices-Lobera P, Márquez-Medina D. Massive hemoptysis after the first administration of pembrolizumab in a strongly positive, centrally located NSCLC. J Thorac Oncol 2018; 13: e76–7.
13 Zarogoulidis P, Athanasiou E, Tsiouda T et al. Immunotherapy “shock” a case series of PD-L1 100% and pembrolizumab first-line treatment. Respir Med Case Rep 2017; 22: 197–202.